The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
408
Change in Mean Pain Severity Score From Baseline to 13 Weeks
Pain severity measured on a Numeric Rating Scale (NRS). Range: 0 (no pain) to 10 (worst possible pain). Change: score at 13 weeks minus score at baseline.
Time frame: Baseline and 13 weeks
Number of Patients With ≥50% Reduction in Mean Pain Severity Score.
Pain severity measured on a Numeric Rating Scale (NRS). Range: 0 (no pain) to 10 (worst possible pain). Assessment of reduction based on change in score at 13 weeks compared to baseline.
Time frame: Baseline and 13 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Mesa, Arizona, United States
Unnamed facility
Peoria, Arizona, United States
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Encino, California, United States
Unnamed facility
Newport Beach, California, United States
Unnamed facility
Walnut Creek, California, United States
Unnamed facility
Pueblo, Colorado, United States
Unnamed facility
New Britain, Connecticut, United States
Unnamed facility
Stratford, Connecticut, United States
Unnamed facility
Waterbury, Connecticut, United States
...and 41 more locations